IMS Health, which provides healthcare data and consulting services to drug makers, payers and healthcare providers, filed on Thursday with the SEC to raise up to $100 million in an initial public offering, although that amount is likely just a placeholder. We estimate the deal will raise between $750 million and $1 billion. The Danbury, CT-based company, which was founded in 1954 and booked $2.5 billion in sales for the 12 months ended September 30, 2013, plans to list on the NYSE under the symbol IMS. J.P. Morgan, Goldman Sachs and Morgan Stanley are the joint bookrunners on the deal. No pricing terms were disclosed.
